Compare · BSX vs INSP
BSX vs INSP
Side-by-side comparison of Boston Scientific Corporation (BSX) and Inspire Medical Systems Inc. (INSP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and INSP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 44.9x INSP ($1.46B).
- Over the past year, BSX is down 57.6% and INSP is down 59.7% - BSX leads by 2.1 points.
- INSP has been more active in the news (7 items in the past 4 weeks vs 1 for BSX).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Inspire Medical Systems Inc.
- Price
- $44.02-1.32%
- $50.50-1.98%
- Market cap
- $65.44B
- $1.46B
- 1M return
- -6.16%
- +22.01%
- 1Y return
- -57.59%
- -59.70%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 7
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest INSP
- Director Melenikiotou Georgia was granted 344 shares, increasing direct ownership by 4% to 8,329 units (SEC Form 4)
- Director Tansey Casey M was granted 346 shares, increasing direct ownership by 1% to 26,632 units (SEC Form 4)
- Director Ellis Gary Lee was granted 581 shares, increasing direct ownership by 5% to 11,419 units (SEC Form 4)
- Director Broader Shelley G was granted 383 shares, increasing direct ownership by 5% to 8,854 units (SEC Form 4)
- Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
- Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
- SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.
- Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Inspire Medical Systems downgraded by Evercore ISI with a new price target
- Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study